A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain

Journal of Pain and Symptom Management

Volumn 47, Issue 1, 2014, Pages 166-173

  Lynch, Mary E ^a,b   Cesar Rittenberg, Paula ^a   Hohmann, Andrea G ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c INDIANA UNIVERSITY   (United States)

Author keywords

cannabinoids; chemotherapy; Neuropathic pain; randomized controlled trial

Indexed keywords

CISPLATIN; NABIXIMOLS; OXALIPLATIN; PACLITAXEL; PLACEBO; VINCRISTINE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CANNABIDIOL; DRONABINOL; DRUG COMBINATION; ORAL SPRAY;

ADULT; ALLODYNIA; ANALGESIA; ANXIETY DISORDER; ARTICLE; BRAIN DYSFUNCTION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NEUROPATHIC PAIN; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERALGESIA; HYPESTHESIA; INCREASED APPETITE; MALE; MIDDLE AGED; MOUTH MUCOSA; NAUSEA; NEUROPATHIC PAIN; ORAL SPRAY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PANIC; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SCOTOMA; SOMNOLENCE; THINKING IMPAIRMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; CHEMICALLY INDUCED; DRUG COMBINATION; NEURALGIA; PAIN MEASUREMENT; TREATMENT OUTCOME;

ANALGESICS; ANTINEOPLASTIC AGENTS; CANNABIDIOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; ORAL SPRAYS; PAIN MEASUREMENT; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84891824524     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2013.02.018     Document Type: Article

References (20)

1. J.P. Cata, H.R. Weng, B.N. Lee, J.M. Reuben, and P.M. Dougherty Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy Minerva Anestesiol 72 2006 151 169
2. P.M. Dougherty, J.P. Cata, J.V. Cordella, A. Burton, and H.R. Weng Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients Pain 109 2004 132 142
3. R.C. Polomano, and G.J. Bennett Chemotherapy-evoked painful peripheral neuropathy Pain Med 2 2001 8 14
4. J.H. Uhm, and W.K. Yung Neurologic complications of cancer therapy Curr Treat Options Neurol 1 1999 428 437
5. J.P. Cata, H.R. Weng, J.H. Chen, and P.M. Dougherty Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia Neuroscience 138 2006 329 338
6. H.R. Weng, J.V. Cordella, and P.M. Dougherty Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia Pain 103 2003 131 138
7. A.G. Nackley, A.M. Zvonok, A. Makriyannis, and A.G. Hohmann Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation J Neurophysiol 92 2004 3562 3574
8. I.A. Khasabova, S. Khasabov, and J. Paz et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy J Neurosci 32 2012 7091 7101
9. E.J. Rahn, and A.G. Hohmann Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Neurotherapeutics 6 2009 713 737
10. E.J. Rahn, A. Makriyannis, and A.G. Hohmann Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats Br J Pharmacol 152 2007 765 777
11. E.J. Rahn, A.M. Zvonok, and G.A. Thakur et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats J Pharmacol Exp Ther 327 2008 584 591
12. D. Pascual, C. Goicoechea, M. Suardíaz, and M.I. Martín A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats Pain 118 2005 23 34
13. L. Deng, J. Guindon, and V.K. Vemuri et al. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy Mol Pain 8 2012 71
14. J. Guindon, Y. Lai, S.M. Takacs, H.B. Bradshaw, and A.G. Hohmann Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment Pharmacol Res 67 2013 94 109
15. G. Vera, A. Chiarlone, and P.A. Cabezos et al. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat Life Sci 81 2007 468 479
16. R.H. Dworkin, D.C. Turk, and J.T. Farrar et al. IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations Pain 113 2005 9 19
17. J.E. Ware, and C.D. Sherbourne The MOS 36-item short form health survey (SF-36) Med Care 30 1992 473 483
18. M.E. Lynch, A.J. Clark, and J. Sawynok Intravenous adenosine alleviates neuropathic pain, a double blind placebo controlled trial using an enriched enrolment design Pain 103 2003 109 115
19. P. Squire, S. Marchand, and M. Ware Using quantitative sensory testing (QST) in chronic pain evaluation: from research to clinical practice Pain Res Manag 13 2008 125
20. N.B. Finnerup, S.H. Sindrup, and T.S. Jensen The evidence for pharmacological treatment of neuropathic pain Pain 150 2010 573 581